Tudorza Pressair (aclidinium; AstraZeneca/Circassia/Kyorin Pharmaceutical) is a twice-daily long-acting muscarinic antagonist indicated for the maintenance treatment of chronic obstructive pulmonary disease (COPD)-associated bronchospasm, bronchitis, and emphysema. Tudorza Pressair received US and EU approvals for use in COPD in July 2012, and Japanese approval in March 2015. In Europe, the drug is marketed under the brand name Eklira Genuair.
LIST OF FIGURES
10 Figure 1: Tudorza Pressair for COPD – SWOT analysis
11 Figure 2: Datamonitor Healthcare’s drug assessment summary of Tudorza Pressair for COPD
12 Figure 3: Datamonitor Healthcare’s drug assessment summary of Tudorza Pressair for COPD
14 Figure 4: Tudorza Pressair sales for COPD across the US, Japan, and major EU markets, by country, 2017–26
LIST OF TABLES
5 Table 1: Tudorza Pressair drug profile
7 Table 2: Tudorza Pressair Phase III data in COPD
15 Table 3: Tudorza Pressair sales for COPD across the US, Japan, and major EU markets, by country ($m), 2017–26
This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.